CPP
BCLI

Crow Point Partners’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

Crow Point Partners’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-1,789
Closed -$104K – 79
2019
Q3 		$104K Hold
1,789
– – 0.02% 119
2019
Q2 		$106K Hold
1,789
– – 0.02% 117
2019
Q1 		$116K Hold
1,789
– – 0.02% 114
2018
Q4 		$90K Hold
1,789
– – 0.02% 117
2018
Q3 		$102K Buy
1,789
+137
+8% +$8.28K 0.02% 157
2018
Q2 		$98K Buy
1,652
+1,222
+284% +$71.9K 0.02% 117
2018
Q1 		$20K Buy
430
+89
+26% +$4.48K ﹤0.01% 243
2017
Q4 		$16K Buy
+341
New +$20.4K ﹤0.01% 248

Other funds holding BCLI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
WG
Winton Group London, United Kingdom $2.85B AUM 30.73% 1-Year Est. Return
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Crow Point Partners's BCLI Position: Q4 2019 in Review

Crow Point Partners sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q4 2019, closing a stake of 1,789 shares — an estimated $104K sold.

Crow Point Partners first reported a position in BCLI in Q4 2017 and held it in 8 quarters. The position peaked at $116K in Q1 2019. 43 funds tracked by Wall St. Rank hold BCLI as of Q4 2019.

  • Crow Point Partners reported no remaining BRAINSTORM CELL THERAPUTC position as of Q4 2019 after selling out during the quarter.
  • Crow Point Partners sold 1,789 BRAINSTORM CELL THERAPUTC shares in Q4 2019, an estimated $104K.
  • Crow Point Partners first reported a position in BRAINSTORM CELL THERAPUTC in Q4 2017 and held it in 8 quarters.
  • Crow Point Partners's BRAINSTORM CELL THERAPUTC position peaked at $116K in Q1 2019.
  • 43 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q4 2019.

Based on Crow Point Partners's 13F filing for Q4 2019, filed 14 Feb 2020.